BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Faivre S, Rimassa L, Finn RS. Molecular therapies for HCC: Looking outside the box. J Hepatol. 2020;72:342-352. [PMID: 31954496 DOI: 10.1016/j.jhep.2019.09.010] [Cited by in Crossref: 90] [Cited by in F6Publishing: 97] [Article Influence: 90.0] [Reference Citation Analysis]
Number Citing Articles
1 Yu CL, Yu YL, Yang SF, Hsu CE, Lin CL, Hsieh YH, Chiou HL. Praeruptorin A reduces metastasis of human hepatocellular carcinoma cells by targeting ERK/MMP1 signaling pathway. Environ Toxicol 2021;36:540-9. [PMID: 33226171 DOI: 10.1002/tox.23059] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
2 Rizzo A. Optimizing outcomes in HCC: Comment on "optimal timing of combining sorafenib with trans-arterial chemoembolization in patients with hepatocellular carcinoma: A meta-analysis" by Jiang et al. Transl Oncol 2021;14:101246. [PMID: 34656968 DOI: 10.1016/j.tranon.2021.101246] [Reference Citation Analysis]
3 Rizzo A, Ricci AD, Di Federico A, Frega G, Palloni A, Tavolari S, Brandi G. Predictive Biomarkers for Checkpoint Inhibitor-Based Immunotherapy in Hepatocellular Carcinoma: Where Do We Stand? Front Oncol 2021;11:803133. [PMID: 34976841 DOI: 10.3389/fonc.2021.803133] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
4 Raevskaya O, Appelman H, Razumilava N. A Contemporary Approach to Diagnosis and Treatment of Combined Hepatocellular-Cholangiocarcinoma. Curr Hepatol Rep 2020;19:478-85. [PMID: 33415066 DOI: 10.1007/s11901-020-00556-4] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
5 Li ZJ, Dai HQ, Huang XW, Feng J, Deng JH, Wang ZX, Yang XM, Liu YJ, Wu Y, Chen PH, Shi H, Wang JG, Zhou J, Lu GD. Artesunate synergizes with sorafenib to induce ferroptosis in hepatocellular carcinoma. Acta Pharmacol Sin 2021;42:301-10. [PMID: 32699265 DOI: 10.1038/s41401-020-0478-3] [Cited by in Crossref: 36] [Cited by in F6Publishing: 27] [Article Influence: 36.0] [Reference Citation Analysis]
6 Jia W, Wang L. Using Traditional Chinese Medicine to Treat Hepatocellular Carcinoma by Targeting Tumor Immunity. Evid Based Complement Alternat Med 2020;2020:9843486. [PMID: 32595757 DOI: 10.1155/2020/9843486] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
7 Jin C, Li Y, Su Y, Guo Z, Wang X, Wang S, Zhang F, Zhang Z, Shao J, Zheng S. Novel copper complex CTB regulates methionine cycle induced TERT hypomethylation to promote HCC cells senescence via mitochondrial SLC25A26. Cell Death Dis 2020;11:844. [PMID: 33041323 DOI: 10.1038/s41419-020-03048-x] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
8 Rodríguez-Tajes S, Pocurull A, Castillo J, Casanova G, Vega L, Lens S, Mariño Z, Londoño MC, Forner A, Torres F, Forns X. Hepatitis C-related cirrhosis will be a marginal cause of hospital admissions by 2025. J Hepatol 2020;73:1360-7. [PMID: 32697948 DOI: 10.1016/j.jhep.2020.07.018] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
9 Bévant K, Coulouarn C. A novel immunosuppression-based classification of liver tumors opens new perspectives for adapted therapeutic strategies. EBioMedicine 2020;54:102737. [PMID: 32268278 DOI: 10.1016/j.ebiom.2020.102737] [Reference Citation Analysis]
10 Wang DX, Yang X, Lin JZ, Bai Y, Long JY, Yang XB, Seery S, Zhao HT. Efficacy and safety of lenvatinib for patients with advanced hepatocellular carcinoma: A retrospective, real-world study conducted in China. World J Gastroenterol 2020; 26(30): 4465-4478 [PMID: 32874058 DOI: 10.3748/wjg.v26.i30.4465] [Cited by in CrossRef: 14] [Cited by in F6Publishing: 12] [Article Influence: 7.0] [Reference Citation Analysis]
11 Huang J, Chen X, Zhu W. MRGBP is a potential novel prognostic biomarker and is correlated with immune infiltrates in hepatocellular carcinoma. Medicine (Baltimore) 2021;100:e25234. [PMID: 33761715 DOI: 10.1097/MD.0000000000025234] [Reference Citation Analysis]
12 Rizzo A, Ricci AD, Brandi G. Atezolizumab in advanced hepatocellular carcinoma: good things come to those who wait. Immunotherapy 2021;13:637-44. [PMID: 33820447 DOI: 10.2217/imt-2021-0026] [Cited by in Crossref: 18] [Cited by in F6Publishing: 14] [Article Influence: 18.0] [Reference Citation Analysis]
13 Souza BNRF, Ribeiro ERFR, da Silva de Barros AO, Pijeira MSO, Kenup-Hernandes HO, Ricci-Junior E, Diniz Filho JFS, Dos Santos CC, Alencar LMR, Attia MF, Gemini-Piperni S, Santos-Oliveira R. Nanomicelles of Radium Dichloride [223Ra]RaCl2 Co-Loaded with Radioactive Gold [198Au]Au Nanoparticles for Targeted Alpha-Beta Radionuclide Therapy of Osteosarcoma. Polymers (Basel) 2022;14:1405. [PMID: 35406278 DOI: 10.3390/polym14071405] [Reference Citation Analysis]
14 Sung PS, Choi MH, Yang H, Lee SK, Chun HJ, Jang JW, Choi JY, Yoon SK, Choi JI, Lee YJ, Bae SH. Diffusion-Weighted Magnetic Resonance Imaging in Hepatocellular Carcinoma as a Predictor of a Response to Cisplatin-Based Hepatic Arterial Infusion Chemotherapy. Front Oncol 2020;10:600233. [PMID: 33330098 DOI: 10.3389/fonc.2020.600233] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
15 Sun EJ, Wankell M, Palamuthusingam P, McFarlane C, Hebbard L. Targeting the PI3K/Akt/mTOR Pathway in Hepatocellular Carcinoma. Biomedicines 2021;9:1639. [PMID: 34829868 DOI: 10.3390/biomedicines9111639] [Reference Citation Analysis]
16 Cammarota A, Zanuso V, D'Alessio A, Pressiani T, Bozzarelli S, Personeni N, Rimassa L. The dual checkpoint blockade in unresectable hepatocellular carcinoma: Opportunities emerging in clinical trials. Expert Opin Investig Drugs 2022. [PMID: 35152830 DOI: 10.1080/13543784.2022.2042253] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
17 Vène E, Jarnouen K, Ribault C, Vlach M, Verres Y, Bourgeois M, Lepareur N, Cammas-marion S, Loyer P. Circumsporozoite Protein of Plasmodium berghei- and George Baker Virus A-Derived Peptides Trigger Efficient Cell Internalization of Bioconjugates and Functionalized Poly(ethylene glycol)-b-poly(benzyl malate)-Based Nanoparticles in Human Hepatoma Cells. Pharmaceutics 2022;14:804. [DOI: 10.3390/pharmaceutics14040804] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
18 Zhao S, Wu W, Jiang H, Ma L, Pan C, Jin C, Mo J, Wang L, Wang K. Selective Inhibitor of the c-Met Receptor Tyrosine Kinase in Advanced Hepatocellular Carcinoma: No Beneficial Effect With the Use of Tivantinib? Front Immunol 2021;12:731527. [PMID: 34804015 DOI: 10.3389/fimmu.2021.731527] [Reference Citation Analysis]
19 Zheng LL, Tao CC, Tao ZG, Zhang K, Wu AK, Wu JX, Rong WQ. Research progress regarding programmed cell death 1/programmed cell death ligand 1 inhibitors combined with targeted therapy for treating hepatocellular carcinoma. World J Gastrointest Surg 2021; 13(10): 1136-1148 [PMID: 34754383 DOI: 10.4240/wjgs.v13.i10.1136] [Reference Citation Analysis]
20 Li YH, Hu YQ, Wang SC, Li Y, Chen DM. LncRNA SNHG5: A new budding star in human cancers. Gene 2020;749:144724. [PMID: 32360843 DOI: 10.1016/j.gene.2020.144724] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 6.5] [Reference Citation Analysis]
21 Wang X, Ge Y, Shi M, Dai H, Liu W, Wang P. Protein kinase N1 promotes proliferation and invasion of liver cancer. Exp Ther Med 2021;21:651. [PMID: 33968181 DOI: 10.3892/etm.2021.10083] [Reference Citation Analysis]
22 Pinato DJ, Kaneko T, Saeed A, Pressiani T, Kaseb A, Wang Y, Szafron D, Jun T, Dharmapuri S, Naqash AR, Muzaffar M, Navaid M, Lee CJ, Bulumulle A, Yu B, Paul S, Nimkar N, Bettinger D, Hildebrand H, Abugabal YI, Ang C, Marron TU, Khan U, Personeni N, Rimassa L, Huang YH. Immunotherapy in Hepatocellular Cancer Patients with Mild to Severe Liver Dysfunction: Adjunctive Role of the ALBI Grade. Cancers (Basel) 2020;12:E1862. [PMID: 32664319 DOI: 10.3390/cancers12071862] [Cited by in Crossref: 15] [Cited by in F6Publishing: 10] [Article Influence: 7.5] [Reference Citation Analysis]
23 Ebeling Barbier C, Heindryckx F, Lennernäs H. Limitations and Possibilities of Transarterial Chemotherapeutic Treatment of Hepatocellular Carcinoma. Int J Mol Sci 2021;22:13051. [PMID: 34884853 DOI: 10.3390/ijms222313051] [Reference Citation Analysis]
24 Dai T, Li J, Lu X, Ye L, Yu H, Zhang L, Deng M, Zhu S, Liu W, Wang G, Yang Y. Prognostic Role and Potential Mechanisms of the Ferroptosis-Related Metabolic Gene Signature in Hepatocellular Carcinoma. Pharmgenomics Pers Med 2021;14:927-45. [PMID: 34377010 DOI: 10.2147/PGPM.S319524] [Reference Citation Analysis]
25 Zelli V, Compagnoni C, Capelli R, Corrente A, Di Vito Nolfi M, Zazzeroni F, Alesse E, Tessitore A. Role of exosomal microRNAs in cancer therapy and drug resistance mechanisms: focus on hepatocellular carcinoma. Front Oncol 2022;12:940056. [DOI: 10.3389/fonc.2022.940056] [Reference Citation Analysis]
26 Wang X, Xing Z, Xu H, Yang H, Xing T. Development and validation of epithelial mesenchymal transition-related prognostic model for hepatocellular carcinoma. Aging (Albany NY) 2021;13:13822-45. [PMID: 33929972 DOI: 10.18632/aging.202976] [Reference Citation Analysis]
27 Dhanasekaran R. Deciphering Tumor Heterogeneity in Hepatocellular Carcinoma (HCC)-Multi-Omic and Singulomic Approaches. Semin Liver Dis 2021;41:9-18. [PMID: 33764481 DOI: 10.1055/s-0040-1722261] [Reference Citation Analysis]
28 Rizzo A. The evolving landscape of systemic treatment for advanced hepatocellular carcinoma and biliary tract cancer. Cancer Treat Res Commun 2021;27:100360. [PMID: 33799005 DOI: 10.1016/j.ctarc.2021.100360] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
29 Zeisel MB, Guerrieri F, Levrero M. Host Epigenetic Alterations and Hepatitis B Virus-Associated Hepatocellular Carcinoma. J Clin Med 2021;10:1715. [PMID: 33923385 DOI: 10.3390/jcm10081715] [Reference Citation Analysis]
30 Xia X, Tang P, Liu H, Li Y. Identification and Validation of an Immune-related Prognostic Signature for Hepatocellular Carcinoma. J Clin Transl Hepatol 2021;9:798-808. [PMID: 34966643 DOI: 10.14218/JCTH.2021.00017] [Reference Citation Analysis]
31 Pavlović N, Heindryckx F. Targeting ER stress in the hepatic tumor microenvironment. FEBS J 2021. [PMID: 34331743 DOI: 10.1111/febs.16145] [Reference Citation Analysis]
32 Zhong FJ, Sun B, Cao MM, Xu C, Li YM, Yang LY. STMN2 mediates nuclear translocation of Smad2/3 and enhances TGFβ signaling by destabilizing microtubules to promote epithelial-mesenchymal transition in hepatocellular carcinoma. Cancer Lett 2021;506:128-41. [PMID: 33705863 DOI: 10.1016/j.canlet.2021.03.001] [Reference Citation Analysis]
33 Yasui Y, Kurosaki M, Tsuchiya K, Hayakawa Y, Hasebe C, Abe M, Ogawa C, Joko K, Ochi H, Tada T, Nakamura S, Furuta K, Kimura H, Tsuji K, Kojima Y, Akahane T, Tamada T, Uchida Y, Kondo M, Mitsuda A, Izumi N; Japanese Red Cross Liver Study Group. Real-World Data on Ramucirumab Therapy including Patients Who Experienced Two or More Systemic Treatments: A Multicenter Study. Cancers (Basel) 2022;14:2975. [PMID: 35740647 DOI: 10.3390/cancers14122975] [Reference Citation Analysis]
34 Li X, Fu Z, Chen X, Cao K, Zhong J, Liu L, Ding N, Zhang X, Zhai J, Qu Z. Efficacy and Safety of Lenvatinib Combined With PD-1 Inhibitors Plus TACE for Unresectable Hepatocellular Carcinoma Patients in China Real-World. Front Oncol 2022;12:950266. [DOI: 10.3389/fonc.2022.950266] [Reference Citation Analysis]
35 Yao M, Yang JL, Wang DF, Wang L, Chen Y, Yao DF. Encouraging specific biomarkers-based therapeutic strategies for hepatocellular carcinoma. World J Clin Cases 2022; 10(11): 3321-3333 [DOI: 10.12998/wjcc.v10.i11.3321] [Reference Citation Analysis]
36 Jin Z, Sun D, Song M, Zhu W, Liu H, Wang J, Shi G, Wang F. Comprehensive Analysis of HOX Family Members as Novel Diagnostic and Prognostic Markers for Hepatocellular Carcinoma. Journal of Oncology 2022;2022:1-17. [DOI: 10.1155/2022/5758601] [Reference Citation Analysis]
37 Yang C, Chen J, Li Y, Huang X, Liu Z, Wang J, Jiang H, Qin W, Lv Y, Wang H, Wang C. Exploring subclass-specific therapeutic agents for hepatocellular carcinoma by informatics-guided drug screen. Brief Bioinform 2021;22:bbaa295. [PMID: 33167027 DOI: 10.1093/bib/bbaa295] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
38 Trojan J. Cabozantinib for the Treatment of Advanced Hepatocellular Carcinoma: Current Data and Future Perspectives. Drugs 2020;80:1203-10. [PMID: 32671719 DOI: 10.1007/s40265-020-01361-5] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 6.0] [Reference Citation Analysis]
39 Li H. Angiogenesis in the progression from liver fibrosis to cirrhosis and hepatocelluar carcinoma. Expert Rev Gastroenterol Hepatol 2021;15:217-33. [PMID: 33131349 DOI: 10.1080/17474124.2021.1842732] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
40 Yi C, Chen L, Lin Z, Liu L, Shao W, Zhang R, Lin J, Zhang J, Zhu W, Jia H, Qin L, Lu L, Chen J. Lenvatinib Targets FGF Receptor 4 to Enhance Antitumor Immune Response of Anti-Programmed Cell Death-1 in HCC. Hepatology 2021;74:2544-60. [PMID: 34036623 DOI: 10.1002/hep.31921] [Cited by in Crossref: 21] [Cited by in F6Publishing: 12] [Article Influence: 21.0] [Reference Citation Analysis]
41 Zhu Q, Ren H, Li X, Qian B, Fan S, Hu F, Xu L, Zhai B. Silencing KIF14 reverses acquired resistance to sorafenib in hepatocellular carcinoma. Aging (Albany NY) 2020;12:22975-3003. [PMID: 33203790 DOI: 10.18632/aging.104028] [Reference Citation Analysis]
42 Kim CG, Kim C, Yoon SE, Kim KH, Choi SJ, Kang B, Kim HR, Park SH, Shin EC, Kim YY, Kim DJ, Chung HC, Chon HJ, Choi HJ, Lim HY. Hyperprogressive disease during PD-1 blockade in patients with advanced hepatocellular carcinoma. J Hepatol. 2021;74:350-359. [PMID: 32810553 DOI: 10.1016/j.jhep.2020.08.010] [Cited by in Crossref: 20] [Cited by in F6Publishing: 25] [Article Influence: 10.0] [Reference Citation Analysis]
43 Hu JW, Chen B, Zhang J, Qi YP, Liang JH, Zhong JH, Xiang BD. Novel combination of celecoxib and metformin improves the antitumor effect by inhibiting the growth of Hepatocellular Carcinoma. J Cancer 2020;11:6437-44. [PMID: 33033527 DOI: 10.7150/jca.47532] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
44 Simoes CC, Thung SN, Fiel MI, Sung MW, Schwartz ME, Ward SC. Morphology of tumor and nontumor tissue in liver resection specimens for hepatocellular carcinoma following nivolumab therapy. Mod Pathol 2021;34:823-33. [PMID: 32989224 DOI: 10.1038/s41379-020-00679-5] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
45 Wang S, Wang X, Yang X, Liu F, Li J, Li W, Bai Z, Wang H, Mao J, Li T, He K, Wang H. Comprehensive kinomic study via a chemical proteomic approach reveals kinome reprogramming in hepatocellular carcinoma tissues. Proteomics 2021;:e2100141. [PMID: 34932872 DOI: 10.1002/pmic.202100141] [Reference Citation Analysis]
46 Rizzo A, Brandi G. First-line Chemotherapy in Advanced Biliary Tract Cancer Ten Years After the ABC-02 Trial: "And Yet It Moves!". Cancer Treat Res Commun 2021;27:100335. [PMID: 33592561 DOI: 10.1016/j.ctarc.2021.100335] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 8.0] [Reference Citation Analysis]
47 Ma Y, Xu R, Liu X, Zhang Y, Song L, Cai S, Zhou S, Xie Y, Li A, Cao W, Tang X. LY3214996 relieves acquired resistance to sorafenib in hepatocellular carcinoma cells. Int J Med Sci 2021;18:1456-64. [PMID: 33628103 DOI: 10.7150/ijms.51256] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
48 He Q, Lin Z, Wang Z, Huang W, Tian D, Liu M, Xia L. SIX4 promotes hepatocellular carcinoma metastasis through upregulating YAP1 and c-MET. Oncogene 2020;39:7279-95. [PMID: 33046796 DOI: 10.1038/s41388-020-01500-y] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
49 Hou Z, Liu J, Jin Z, Qiu G, Xie Q, Mi S, Huang J. Use of chemotherapy to treat hepatocellular carcinoma. Biosci Trends 2022. [PMID: 35173139 DOI: 10.5582/bst.2022.01044] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
50 Yang Y, Chen Y, Zhang X, Xin Y, Wang Y, Li X, Fan Q, Zhou X, Ye F. Predictors and patterns of recurrence after radiofrequency ablation for hepatocellular carcinoma within up-to-seven criteria: A multicenter retrospective study. Eur J Radiol 2021;138:109623. [PMID: 33711573 DOI: 10.1016/j.ejrad.2021.109623] [Reference Citation Analysis]
51 Rizzo A, Ricci AD, Brandi G. Immune-based combinations for advanced hepatocellular carcinoma: shaping the direction of first-line therapy. Future Oncol 2021;17:755-7. [PMID: 33508960 DOI: 10.2217/fon-2020-0986] [Cited by in Crossref: 18] [Cited by in F6Publishing: 13] [Article Influence: 18.0] [Reference Citation Analysis]
52 She S, Ren L, Chen P, Wang M, Chen D, Wang Y, Chen H. Functional Roles of Chemokine Receptor CCR2 and Its Ligands in Liver Disease. Front Immunol 2022;13:812431. [DOI: 10.3389/fimmu.2022.812431] [Reference Citation Analysis]
53 Li Y, He X, Zhang X, Xu Y, Chen W, Liu X, Xu X. RMI2 is a prognostic biomarker and promotes tumor growth in hepatocellular carcinoma. Clin Exp Med 2021. [PMID: 34275027 DOI: 10.1007/s10238-021-00742-8] [Reference Citation Analysis]
54 Chen Y, Hu H, Yuan X, Fan X, Zhang C. Advances in Immune Checkpoint Inhibitors for Advanced Hepatocellular Carcinoma. Front Immunol 2022;13:896752. [PMID: 35757756 DOI: 10.3389/fimmu.2022.896752] [Reference Citation Analysis]
55 Guan J, Pan Y, Li H, Zhu Y, Gao Y, Wang J, Zhou Y, Guan Z, Yang Z. Activity and Tissue Distribution of Antisense Oligonucleotide CT102 Encapsulated with Cytidinyl/Cationic Lipid against Hepatocellular Carcinoma. Mol Pharm 2022. [PMID: 35508302 DOI: 10.1021/acs.molpharmaceut.2c00026] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
56 Dourthe C, Julien C, Di Tommaso S, Dupuy JW, Dugot-Senant N, Brochard A, Le Bail B, Blanc JF, Chiche L, Balabaud C, Bioulac-Sage P, Saltel F, Raymond AA. Proteomic Profiling of Hepatocellular Adenomas Paves the Way to Diagnostic and Prognostic Approaches. Hepatology 2021;74:1595-610. [PMID: 33754354 DOI: 10.1002/hep.31826] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
57 Li B, Li A, You Z, Xu J, Zhu S. Epigenetic silencing of CDKN1A and CDKN2B by SNHG1 promotes the cell cycle, migration and epithelial-mesenchymal transition progression of hepatocellular carcinoma. Cell Death Dis 2020;11:823. [PMID: 33009370 DOI: 10.1038/s41419-020-03031-6] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
58 Schipilliti FM, Garajová I, Rovesti G, Balsano R, Piacentini F, Dominici M, Gelsomino F. The Growing Skyline of Advanced Hepatocellular Carcinoma Treatment: A Review. Pharmaceuticals (Basel) 2021;14:43. [PMID: 33429973 DOI: 10.3390/ph14010043] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
59 Liang B, Zhou Y, Qian M, Xu M, Wang J, Zhang Y, Song X, Wang H, Lin S, Ren C, Monga SP, Wang B, Evert M, Chen Y, Chen X, Huang Z, Calvisi DF, Chen X. TBX3 functions as a tumor suppressor downstream of activated CTNNB1 mutants during hepatocarcinogenesis. J Hepatol 2021;75:120-31. [PMID: 33577921 DOI: 10.1016/j.jhep.2021.01.044] [Reference Citation Analysis]
60 He Q, Huang W, Liu D, Zhang T, Wang Y, Ji X, Xie M, Sun M, Tian D, Liu M, Xia L. Homeobox B5 promotes metastasis and poor prognosis in Hepatocellular Carcinoma, via FGFR4 and CXCL1 upregulation. Theranostics 2021;11:5759-77. [PMID: 33897880 DOI: 10.7150/thno.57659] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 6.0] [Reference Citation Analysis]
61 Shan L, Wang F, Zhai D, Meng X, Liu J, Lv X. New Drugs for Hepatic Fibrosis. Front Pharmacol 2022;13:874408. [DOI: 10.3389/fphar.2022.874408] [Reference Citation Analysis]
62 Zhang Z, Shang J, Hu B, Shi H, Cao Y, Li J, Jiao T, Zhang W, Lu S. Prognosis and Tumour Immune Microenvironment of Patients With Hepatocellular Carcinoma by a Novel Pyroptosis-Related lncRNA Signature. Front Immunol 2022;13:836576. [DOI: 10.3389/fimmu.2022.836576] [Reference Citation Analysis]
63 Gan C, Zhou K, Li M, Shang J, Liu L, Zhao Q. NUP153 promotes HCC cells proliferation via c-Myc-mediated downregulation of P15INK4b. Digestive and Liver Disease 2022. [DOI: 10.1016/j.dld.2022.02.008] [Reference Citation Analysis]
64 Cammarota A, Zanuso V, D’alessio A, Pressiani T, Personeni N, Rimassa L. Cabozantinib plus atezolizumab for the treatment of advanced hepatocellular carcinoma: Shedding light on the preclinical rationale and clinical trials. Expert Opinion on Investigational Drugs. [DOI: 10.1080/13543784.2022.2032641] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
65 Finn RS, Ikeda M, Zhu AX, Sung MW, Baron AD, Kudo M, Okusaka T, Kobayashi M, Kumada H, Kaneko S, Pracht M, Mamontov K, Meyer T, Kubota T, Dutcus CE, Saito K, Siegel AB, Dubrovsky L, Mody K, Llovet JM. Phase Ib Study of Lenvatinib Plus Pembrolizumab in Patients With Unresectable Hepatocellular Carcinoma. J Clin Oncol 2020;38:2960-70. [PMID: 32716739 DOI: 10.1200/JCO.20.00808] [Cited by in Crossref: 100] [Cited by in F6Publishing: 100] [Article Influence: 50.0] [Reference Citation Analysis]
66 Xu G, Jin B, Xian X, Yang H, Zhao H, Du S, Makuuchi M, Pawlik TM, Mao Y. Evolutions in the Management of Hepatocellular Carcinoma over Last 4 Decades: An Analysis from the 100 Most Influential Articles in the Field. Liver Cancer 2021;10:137-50. [PMID: 33977090 DOI: 10.1159/000513412] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
67 Roderburg C, Özdirik B, Wree A, Demir M, Tacke F. Systemic treatment of hepatocellular carcinoma: from sorafenib to combination therapies. Hepat Oncol 2020;7:HEP20. [PMID: 32647565 DOI: 10.2217/hep-2020-0004] [Cited by in Crossref: 9] [Cited by in F6Publishing: 11] [Article Influence: 4.5] [Reference Citation Analysis]
68 Zhao Z, Zheng Z, Huang J, Wang J, Peng T, Lin Y, Jian Z. Expression of ALG3 in Hepatocellular Carcinoma and Its Clinical Implication. Front Mol Biosci 2022;9:816102. [DOI: 10.3389/fmolb.2022.816102] [Reference Citation Analysis]
69 Ouyang X, Lv L, Zhao Y, Zhang F, Hu Q, Li Z, Zhu D, Li L. ASF1B Serves as a Potential Therapeutic Target by Influencing Cell Cycle and Proliferation in Hepatocellular Carcinoma. Front Oncol 2021;11:801506. [PMID: 35087760 DOI: 10.3389/fonc.2021.801506] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
70 Okuda K, Umemura A, Kataoka S, Yano K, Takahashi A, Okishio S, Taketani H, Seko Y, Nishikawa T, Yamaguchi K, Moriguchi M, Nakagawa H, Liu Y, Mitsumoto Y, Kanbara Y, Shima T, Okanoue T, Itoh Y. Enhanced Antitumor Effect in Liver Cancer by Amino Acid Depletion-Induced Oxidative Stress. Front Oncol 2021;11:758549. [PMID: 34796113 DOI: 10.3389/fonc.2021.758549] [Reference Citation Analysis]
71 Gu Y, Chen B, Guo D, Pan L, Luo X, Tang J, Yang W, Zhang Y, Zhang L, Huang J, Duan R, Wang Z, Zhang J. Up-Regulation of RACGAP1 Promotes Progressions of Hepatocellular Carcinoma Regulated by GABPA via PI3K/AKT Pathway. Oxidative Medicine and Cellular Longevity 2022;2022:1-16. [DOI: 10.1155/2022/3034150] [Reference Citation Analysis]
72 Lambrecht C, Ferreira GB, Omella JD, Libbrecht L, DE Vos R, Derua R, Mathieu C, Overbergh L, Waelkens E, Janssens V. Differential Proteomic Analysis of Hepatocellular Carcinomas from Ppp2r5d Knockout Mice and Normal (Knockout) Livers. Cancer Genomics Proteomics 2020;17:669-85. [PMID: 33099469 DOI: 10.21873/cgp.20222] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
73 Campani C, Rimassa L, Personeni N, Marra F. Angiogenesis inhibitors for advanced hepatocellular carcinoma: in search for the right partner. Ann Transl Med 2020;8:1532. [PMID: 33313277 DOI: 10.21037/atm-20-3788] [Reference Citation Analysis]
74 Chisari A, Golán I, Campisano S, Gélabert C, Moustakas A, Sancho P, Caja L. Glucose and Amino Acid Metabolic Dependencies Linked to Stemness and Metastasis in Different Aggressive Cancer Types. Front Pharmacol 2021;12:723798. [PMID: 34588983 DOI: 10.3389/fphar.2021.723798] [Reference Citation Analysis]
75 Zhang S, Lu Y, Jiang HY, Cheng ZM, Wei ZJ, Wei YH, Liu T, Xia BJ, Zhao XY, Huang Y, Zou X, Liu R, Zhou S. CircC16orf62 promotes hepatocellular carcinoma progression through the miR-138-5p/PTK2/AKT axis. Cell Death Dis 2021;12:597. [PMID: 34108451 DOI: 10.1038/s41419-021-03866-7] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
76 D'Alessio A, Cammarota A, Prete MG, Pressiani T, Rimassa L. The evolving treatment paradigm of advanced hepatocellular carcinoma: putting all the pieces back together. Curr Opin Oncol 2021;33:386-94. [PMID: 33867478 DOI: 10.1097/CCO.0000000000000744] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
77 Wang DX, Yang X, Lin JZ, Bai Y, Long JY, Yang XB, Seery S, Zhao HT. Efficacy and safety of lenvatinib for patients with advanced hepatocellular carcinoma: A retrospective, real-world study conducted in China. World J Gastroenterol 2020;26:4465-78. [PMID: 32874058 DOI: 10.3748/wjg.v26.i30.4465] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
78 Regan-Fendt K, Li D, Reyes R, Yu L, Wani NA, Hu P, Jacob ST, Ghoshal K, Payne PRO, Motiwala T. Transcriptomics-Based Drug Repurposing Approach Identifies Novel Drugs against Sorafenib-Resistant Hepatocellular Carcinoma. Cancers (Basel) 2020;12:E2730. [PMID: 32977582 DOI: 10.3390/cancers12102730] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
79 D'Alessio A, Rimassa L, Cortellini A, Pinato DJ. PD-1 Blockade for Hepatocellular Carcinoma: Current Research and Future Prospects. J Hepatocell Carcinoma 2021;8:887-97. [PMID: 34386437 DOI: 10.2147/JHC.S284440] [Reference Citation Analysis]
80 Zhang Y, Zhang R, Zeng L, Wang H, Peng R, Zhang M, Zhang H, Yang Z, Gao L, Wang M, Liu J, Petrenko Y. Identification and Validation of a Potential Stemness-Associated Biomarker in Hepatocellular Carcinoma. Stem Cells International 2022;2022:1-18. [DOI: 10.1155/2022/1534593] [Reference Citation Analysis]
81 Piñero F, Dirchwolf M, Pessôa MG. Biomarkers in Hepatocellular Carcinoma: Diagnosis, Prognosis and Treatment Response Assessment. Cells 2020;9:E1370. [PMID: 32492896 DOI: 10.3390/cells9061370] [Cited by in Crossref: 12] [Cited by in F6Publishing: 18] [Article Influence: 6.0] [Reference Citation Analysis]
82 Qu C, He L, Yao N, Li J, Jiang Y, Li B, Peng S, Hu K, Chen D, Chen G, Huang W, Cao M, Fan J, Yuan Y, Ye W, Hong J. Myofibroblast-Specific Msi2 Knockout Inhibits HCC Progression in a Mouse Model. Hepatology 2021;74:458-73. [PMID: 33609283 DOI: 10.1002/hep.31754] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
83 Rinaldi L, Vetrano E, Rinaldi B, Galiero R, Caturano A, Salvatore T, Sasso FC. HCC and Molecular Targeting Therapies: Back to the Future. Biomedicines 2021;9:1345. [PMID: 34680462 DOI: 10.3390/biomedicines9101345] [Reference Citation Analysis]
84 Reinders M, Braat A, Lam M. Toxicity and dosimetry in SORAMIC study. J Hepatol 2020;73:734-5. [PMID: 32622664 DOI: 10.1016/j.jhep.2020.03.045] [Reference Citation Analysis]
85 Rizzo A, Ricci AD, Gadaleta-Caldarola G, Brandi G. First-line immune checkpoint inhibitor-based combinations in unresectable hepatocellular carcinoma: current management and future challenges. Expert Rev Gastroenterol Hepatol 2021;15:1245-51. [PMID: 34431725 DOI: 10.1080/17474124.2021.1973431] [Reference Citation Analysis]
86 Guo Y, Wang J, Benedict B, Yang C, van Gemert F, Ma X, Gao D, Wang H, Zhang S, Lieftink C, Beijersbergen RL, Te Riele H, Qiao X, Gao Q, Sun C, Qin W, Bernards R, Wang C. Targeting CDC7 potentiates ATR-CHK1 signaling inhibition through induction of DNA replication stress in liver cancer. Genome Med 2021;13:166. [PMID: 34663432 DOI: 10.1186/s13073-021-00981-0] [Reference Citation Analysis]
87 D'Alessio A, Cammarota A, Zanuso V, Pressiani T, Personeni N, Rimassa L. Atezolizumab plus bevacizumab for unresectable or metastatic hepatocellular carcinoma. Expert Rev Anticancer Ther 2021;21:927-39. [PMID: 34167423 DOI: 10.1080/14737140.2021.1948329] [Reference Citation Analysis]
88 Peña-Asensio J, Calvo H, Torralba M, Miquel J, Sanz-de-Villalobos E, Larrubia JR. Anti-PD-1/PD-L1 Based Combination Immunotherapy to Boost Antigen-Specific CD8+ T Cell Response in Hepatocellular Carcinoma. Cancers (Basel) 2021;13:1922. [PMID: 33923463 DOI: 10.3390/cancers13081922] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
89 Rizzo A, Dadduzio V, Ricci AD, Massari F, Di Federico A, Gadaleta-Caldarola G, Brandi G. Lenvatinib plus pembrolizumab: the next frontier for the treatment of hepatocellular carcinoma? Expert Opin Investig Drugs 2021;:1-8. [PMID: 34167433 DOI: 10.1080/13543784.2021.1948532] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
90 Rizzo A, Cusmai A, Gadaleta-Caldarola G, Palmiotti G. Which role for predictors of response to immune checkpoint inhibitors in hepatocellular carcinoma? Expert Rev Gastroenterol Hepatol 2022;16:333-9. [PMID: 35403533 DOI: 10.1080/17474124.2022.2064273] [Reference Citation Analysis]
91 Giannis D, Morsy S, Geropoulos G, Esagian SM, Sioutas GS, Moris D. The Epidemiology, Staging and Outcomes of Sarcomatoid Hepatocellular Carcinoma: A SEER Population Analysis. In Vivo 2021;35:393-9. [PMID: 33402488 DOI: 10.21873/invivo.12270] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
92 Rimassa L. Novel Therapies for Hepatocellular Carcinoma. Cancers (Basel) 2020;12:E3049. [PMID: 33092015 DOI: 10.3390/cancers12103049] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
93 Yang T, Xu R, Huo J, Wang B, Du X, Dai B, Zhu M, Zhan Y, Zhang D, Zhang Y. WWOX activation by toosendanin suppresses hepatocellular carcinoma metastasis through JAK2/Stat3 and Wnt/β-catenin signaling. Cancer Lett 2021;513:50-62. [PMID: 34015398 DOI: 10.1016/j.canlet.2021.05.010] [Reference Citation Analysis]
94 Cao L, Zhu YQ, Wu ZX, Wang GX, Cheng HW. Engineering nanotheranostic strategies for liver cancer. World J Gastrointest Oncol 2021; 13(10): 1213-1228 [PMID: 34721763 DOI: 10.4251/wjgo.v13.i10.1213] [Reference Citation Analysis]
95 Gungor MZ, Uysal M, Senturk S. The Bright and the Dark Side of TGF-β Signaling in Hepatocellular Carcinoma: Mechanisms, Dysregulation, and Therapeutic Implications. Cancers (Basel) 2022;14:940. [PMID: 35205692 DOI: 10.3390/cancers14040940] [Reference Citation Analysis]
96 Ceballos MP, Angel A, Delprato CB, Livore VI, Ferretti AC, Lucci A, Comanzo CG, Alvarez ML, Quiroga AD, Mottino AD, Carrillo MC. Sirtuin 1 and 2 inhibitors enhance the inhibitory effect of sorafenib in hepatocellular carcinoma cells. Eur J Pharmacol 2021;892:173736. [PMID: 33220273 DOI: 10.1016/j.ejphar.2020.173736] [Cited by in Crossref: 2] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
97 Wang TT, Hong YF, Chen ZH, Wu DH, Li Y, Wu XY, Huang HQ, Zhang Q, Jia CC. Synergistic effects of α-Mangostin and sorafenib in hepatocellular carcinoma: New insights into α-mangostin cytotoxicity. Biochem Biophys Res Commun 2021;558:14-21. [PMID: 33894673 DOI: 10.1016/j.bbrc.2021.04.047] [Reference Citation Analysis]
98 Muhammed A, D'Alessio A, Enica A, Talbot T, Fulgenzi CAM, Nteliopoulos G, Goldin RD, Cortellini A, Pinato DJ. Predictive biomarkers of response to immune checkpoint inhibitors in hepatocellular carcinoma. Expert Rev Mol Diagn 2022. [PMID: 35236211 DOI: 10.1080/14737159.2022.2049244] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
99 Nault JC, Cheng AL, Sangro B, Llovet JM. Milestones in the pathogenesis and management of primary liver cancer. J Hepatol 2020;72:209-14. [PMID: 31954486 DOI: 10.1016/j.jhep.2019.11.006] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 13.0] [Reference Citation Analysis]
100 Pinato DJ, Valeri N, Muhammed A, Cortellini A. Therapeutic targeting of VEGFR2 in HBV-associated hepatocellular carcinoma. Lancet Gastroenterol Hepatol 2021;6:515-6. [PMID: 33971142 DOI: 10.1016/S2468-1253(21)00134-5] [Reference Citation Analysis]
101 Yim SY, Lee JS. An Overview of the Genomic Characterization of Hepatocellular Carcinoma. J Hepatocell Carcinoma 2021;8:1077-88. [PMID: 34522690 DOI: 10.2147/JHC.S270533] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
102 Alfano V, Zeisel MB, Levrero M, Guerrieri F. The lncRNAs in HBV-Related HCCs: Targeting Chromatin Dynamics and Beyond. Cancers (Basel) 2021;13:3115. [PMID: 34206504 DOI: 10.3390/cancers13133115] [Reference Citation Analysis]
103 Pascut D, Pratama MY, Vo NVT, Masadah R, Tiribelli C. The Crosstalk between Tumor Cells and the Microenvironment in Hepatocellular Carcinoma: The Role of Exosomal microRNAs and their Clinical Implications. Cancers (Basel) 2020;12:E823. [PMID: 32235370 DOI: 10.3390/cancers12040823] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 6.5] [Reference Citation Analysis]
104 Zeng Z, Shi Z, Liu Y, Zhao J, Lu Q, Guo J, Liu X, Huang D, Xu Q. HIF-1α-activated TM4SF1-AS1 promotes the proliferation, migration, and invasion of hepatocellular carcinoma cells by enhancing TM4SF1 expression. Biochem Biophys Res Commun 2021;566:80-6. [PMID: 34118595 DOI: 10.1016/j.bbrc.2021.06.011] [Reference Citation Analysis]
105 Okushin K, Tateishi R, Takahashi A, Uchino K, Nakagomi R, Nakatsuka T, Minami T, Sato M, Fujishiro M, Hasegawa K, Eguchi Y, Kanto T, Kubo S, Yoshiji H, Miyata H, Izumi N, Kudo M, Koike K. Current status of primary liver cancer and decompensated cirrhosis in Japan: launch of a nationwide registry for advanced liver diseases (REAL). J Gastroenterol 2022. [PMID: 35788887 DOI: 10.1007/s00535-022-01893-5] [Reference Citation Analysis]
106 Sharma R, Pillai A, Marron TU, Fessas P, Saeed A, Jun T, Dharmapuri S, Szafron D, Naqash AR, Gampa A, Wang Y, Khan U, Muzaffar M, Lee CJ, Lee PC, Bulumulle A, Paul S, Bettinger D, Hildebrand H, Yehia M, Pressiani T, Kaseb A, Huang YH, Ang C, Kudo M, Nishida N, Personeni N, Rimassa L, Pinato DJ. Patterns and outcomes of subsequent therapy after immune checkpoint inhibitor discontinuation in HCC. Hepatol Commun 2022. [PMID: 35481940 DOI: 10.1002/hep4.1927] [Reference Citation Analysis]
107 Lei X, Shao C, Shou X, Shi K, Shi L, Zhao Y. Porous hydrogel arrays for hepatoma cell spheroid formation and drug resistance investigation. Bio-des Manuf 2021;4:842-50. [DOI: 10.1007/s42242-021-00141-8] [Reference Citation Analysis]
108 Hedrich V, Breitenecker K, Djerlek L, Ortmayr G, Mikulits W. Intrinsic and Extrinsic Control of Hepatocellular Carcinoma by TAM Receptors. Cancers (Basel) 2021;13:5448. [PMID: 34771611 DOI: 10.3390/cancers13215448] [Reference Citation Analysis]
109 Wang Y, Miao X, Jiang Y, Wu Z, Zhu X, Liu H, Wu X, Cai J, Ding X, Gong W. The synergistic antitumor effect of IL-6 neutralization with NVP-BEZ235 in hepatocellular carcinoma. Cell Death Dis 2022;13:146. [PMID: 35165269 DOI: 10.1038/s41419-022-04583-5] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
110 Mo Z, Ding H, Zhou X, Zeng Z, Long L. Gd-EOB-DTPA-enhanced magnetic resonance imaging may help identify patients with hepatocellular carcinoma eligible for treatment targeted at RAF1. Abdom Radiol (NY) 2022;47:209-20. [PMID: 34738148 DOI: 10.1007/s00261-021-03325-z] [Reference Citation Analysis]
111 Gallage S, García-beccaria M, Szydlowska M, Rahbari M, Mohr R, Tacke F, Heikenwalder M. The therapeutic landscape of hepatocellular carcinoma. Med 2021;2:505-52. [DOI: 10.1016/j.medj.2021.03.002] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
112 Yin J, Zhang GC, Fang Y, Yu XN, Liu TT, Dong L, Shen XZ. Prp19 Facilitated p21-Dependent Senescence of Hepatocellular Carcinoma Cells. J Oncol 2022;2022:5705896. [PMID: 35356253 DOI: 10.1155/2022/5705896] [Reference Citation Analysis]
113 Wang Y, Jiang M, Zhu J, Qu J, Qin K, Zhao D, Wang L, Dong L, Zhang X. The safety and efficacy of lenvatinib combined with immune checkpoint inhibitors therapy for advanced hepatocellular carcinoma. Biomed Pharmacother 2020;132:110797. [PMID: 33068935 DOI: 10.1016/j.biopha.2020.110797] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
114 Nishida N, Kudo M. Immune Phenotype and Immune Checkpoint Inhibitors for the Treatment of Human Hepatocellular Carcinoma. Cancers (Basel) 2020;12:E1274. [PMID: 32443599 DOI: 10.3390/cancers12051274] [Cited by in Crossref: 5] [Cited by in F6Publishing: 8] [Article Influence: 2.5] [Reference Citation Analysis]
115 Ng KT, Yeung OW, Liu J, Li CX, Liu H, Liu XB, Qi X, Ma YY, Lam YF, Lau MY, Qiu WQ, Shiu HC, Lai MK, Lo CM, Man K. Clinical significance and functional role of transmembrane protein 47 (TMEM47) in chemoresistance of hepatocellular carcinoma. Int J Oncol 2020;57:956-66. [PMID: 32945373 DOI: 10.3892/ijo.2020.5104] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
116 Zheng Q, Jia J, Zhou Z, Chu Q, Lian W, Chen Z. The Emerging Role of Thymopoietin-Antisense RNA 1 as Long Noncoding RNA in the Pathogenesis of Human Cancers. DNA Cell Biol 2021;40:848-57. [PMID: 34096793 DOI: 10.1089/dna.2021.0024] [Reference Citation Analysis]
117 Granito A, Marinelli S, Forgione A, Renzulli M, Benevento F, Piscaglia F, Tovoli F. Regorafenib Combined with Other Systemic Therapies: Exploring Promising Therapeutic Combinations in HCC. J Hepatocell Carcinoma 2021;8:477-92. [PMID: 34079777 DOI: 10.2147/JHC.S251729] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 6.0] [Reference Citation Analysis]
118 Cramer T, Vaupel P. Severe hypoxia is a typical characteristic of human hepatocellular carcinoma: Scientific fact or fallacy? J Hepatol 2022:S0168-8278(21)02305-9. [PMID: 34990751 DOI: 10.1016/j.jhep.2021.12.028] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 4.0] [Reference Citation Analysis]
119 Ferrer-Fàbrega J, Forner A. Is downstaging a reliable strategy for expanding criteria for liver transplantation in hepatocellular carcinoma? Lancet Oncol 2020;21:867-9. [PMID: 32615100 DOI: 10.1016/S1470-2045(20)30333-8] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
120 Granito A, Forgione A, Marinelli S, Renzulli M, Ielasi L, Sansone V, Benevento F, Piscaglia F, Tovoli F. Experience with regorafenib in the treatment of hepatocellular carcinoma. Therap Adv Gastroenterol 2021;14:17562848211016959. [PMID: 34104211 DOI: 10.1177/17562848211016959] [Cited by in Crossref: 29] [Cited by in F6Publishing: 23] [Article Influence: 29.0] [Reference Citation Analysis]
121 Ren H, Zheng J, Cheng Q, Yang X, Fu Q. Establishment of a Necroptosis-Related Prognostic Signature to Reveal Immune Infiltration and Predict Drug Sensitivity in Hepatocellular Carcinoma. Front Genet 2022;13:900713. [DOI: 10.3389/fgene.2022.900713] [Reference Citation Analysis]
122 Wu G, Wu J, Li Z, Shi S, Wu D, Wang X, Xu H, Liu H, Huang Y, Wang R, Shen J, Dong Z, Wang S. Development of digital organ-on-a-chip to assess hepatotoxicity and extracellular vesicle-based anti-liver cancer immunotherapy. Bio-des Manuf . [DOI: 10.1007/s42242-022-00188-1] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
123 Zhou J, Shao Q, Lu Y, Li Y, Xu Z, Zhou B, Chen Q, Li X, Xu X, Pan Y, Deng Z, Wang Y, Yu Y, Gu J. Monocarboxylate transporter upregulation in induced regulatory T cells promotes resistance to anti-PD-1 therapy in hepatocellular carcinoma patients. Front Oncol 2022;12:960066. [DOI: 10.3389/fonc.2022.960066] [Reference Citation Analysis]
124 Ocker M, Neureiter D. Predicting the outcome of patients with hepatocellular carcinoma: new approaches beyond established clinical scoring systems. Expert Rev Gastroenterol Hepatol 2021;15:111-3. [PMID: 32985933 DOI: 10.1080/17474124.2021.1829472] [Reference Citation Analysis]
125 Vitale G, Gitto S, Campani C, Turco L, Baldan A, Marra F, Morelli MC. Biological therapies in patients with liver disease: are they really lifesavers? Expert Opin Biol Ther 2021;:1-18. [PMID: 34860629 DOI: 10.1080/14712598.2022.2013799] [Reference Citation Analysis]
126 Rizzo A, Ricci AD. Predictors of response for hepatocellular carcinoma immunotherapy: is there anything on the horizon? Expert Review of Precision Medicine and Drug Development 2022;7:50-7. [DOI: 10.1080/23808993.2022.2075724] [Reference Citation Analysis]
127 Li TE, Wang S, Shen XT, Zhang Z, Chen M, Wang H, Zhu Y, Xu D, Hu BY, Wei R, Zheng Y, Dong QZ, Qin LX. PKM2 Drives Hepatocellular Carcinoma Progression by Inducing Immunosuppressive Microenvironment. Front Immunol 2020;11:589997. [PMID: 33193421 DOI: 10.3389/fimmu.2020.589997] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
128 Wu MY, Wang CC, Chang YC, Yu CY, Sung WW, Chen CJ, Tsai MC. The Therapeutic Role of PNU-74654 in Hepatocellular Carcinoma May Involve Suppression of NF-κB Signaling. Medicina (Kaunas) 2022;58:798. [PMID: 35744061 DOI: 10.3390/medicina58060798] [Reference Citation Analysis]
129 Ngo MT, Peng SW, Kuo YC, Lin CY, Wu MH, Chuang CH, Kao CX, Jeng HY, Lin GW, Ling TY, Chang TS, Huang YH. A Yes-Associated Protein (YAP) and Insulin-Like Growth Factor 1 Receptor (IGF-1R) Signaling Loop Is Involved in Sorafenib Resistance in Hepatocellular Carcinoma. Cancers (Basel) 2021;13:3812. [PMID: 34359714 DOI: 10.3390/cancers13153812] [Reference Citation Analysis]
130 Li W, Li Y, Li P, Ma F, Liu M, Kong S, Xue H. miR-200a-3p- and miR-181-5p-Mediated HOXB5 Upregulation Promotes HCC Progression by Transcriptional Activation of EGFR. Front Oncol 2022;12:822760. [PMID: 35847904 DOI: 10.3389/fonc.2022.822760] [Reference Citation Analysis]
131 Feng J, Li J, Wu L, Yu Q, Ji J, Wu J, Dai W, Guo C. Emerging roles and the regulation of aerobic glycolysis in hepatocellular carcinoma. J Exp Clin Cancer Res 2020;39:126. [PMID: 32631382 DOI: 10.1186/s13046-020-01629-4] [Cited by in Crossref: 23] [Cited by in F6Publishing: 30] [Article Influence: 11.5] [Reference Citation Analysis]
132 Philips CA, Rajesh S, Nair DC, Ahamed R, Abduljaleel JK, Augustine P. Hepatocellular Carcinoma in 2021: An Exhaustive Update. Cureus 2021;13:e19274. [PMID: 34754704 DOI: 10.7759/cureus.19274] [Reference Citation Analysis]
133 Mantovani S, Oliviero B, Varchetta S, Mele D, Mondelli MU. Natural Killer Cell Responses in Hepatocellular Carcinoma: Implications for Novel Immunotherapeutic Approaches. Cancers (Basel). 2020;12. [PMID: 32283827 DOI: 10.3390/cancers12040926] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 6.5] [Reference Citation Analysis]
134 Cabibbo G, Celsa C, Enea M, Battaglia S, Rizzo GEM, Busacca A, Matranga D, Attanasio M, Reig M, Craxì A, Cammà C. Progression-Free Survival Early Assessment Is a Robust Surrogate Endpoint of Overall Survival in Immunotherapy Trials of Hepatocellular Carcinoma. Cancers (Basel) 2020;13:E90. [PMID: 33396833 DOI: 10.3390/cancers13010090] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
135 Chinnadurai R, Porter AP, Patel M, Lipat AJ, Forsberg MH, Rajan D, Hematti P, Capitini CM, Bruker C. Hepatocellular Carcinoma Cells Are Protected From Immunolysis by Mesenchymal Stromal Cells Through Indoleamine 2,3 Dioxygenase. Front Cell Dev Biol 2021;9:715905. [PMID: 34869307 DOI: 10.3389/fcell.2021.715905] [Reference Citation Analysis]
136 Wang H, He X, Fang D, Wang X, Guan J, Shi Z, Chen X. Gemcitabine-facilitated modulation of the tumor microenvironment and PD-1/PD-L1 blockade generate a synergistic antitumor effect in a murine hepatocellular carcinoma model. Clinics and Research in Hepatology and Gastroenterology 2021. [DOI: 10.1016/j.clinre.2021.101853] [Reference Citation Analysis]
137 Tsai HM, Han MZ, Lin YJ, Chang TT, Chen CY, Cheng PN, Chuang CH, Wu IC, Chen PJ, Kang JW, Chiu YC, Chiu HC, Chien SC, Kuo HY. Real-world outcome of immune checkpoint inhibitors for advanced hepatocellular carcinoma with macrovascular tumor thrombosis. Cancer Immunol Immunother 2021;70:1929-37. [PMID: 33409737 DOI: 10.1007/s00262-020-02845-9] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
138 Brossard C, Vlach M, Vène E, Ribault C, Dorcet V, Noiret N, Loyer P, Lepareur N, Cammas-Marion S. Synthesis of Poly(Malic Acid) Derivatives End-Functionalized with Peptides and Preparation of Biocompatible Nanoparticles to Target Hepatoma Cells. Nanomaterials (Basel) 2021;11:958. [PMID: 33918663 DOI: 10.3390/nano11040958] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
139 Rizzo A. Tyrosine kinase inhibitors plus immune checkpoint inhibitors as neoadjuvant therapy for hepatocellular carcinoma: an emerging option? Expert Opin Investig Drugs 2021;:1-3. [PMID: 34176423 DOI: 10.1080/13543784.2021.1948533] [Reference Citation Analysis]
140 Ma Z, Li Z, Wang S, Zhou Q, Ma Z, Liu C, Huang B, Zheng Z, Yang L, Zou Y, Zhang C, Huang S, Hou B. SLC39A10 Upregulation Predicts Poor Prognosis, Promotes Proliferation and Migration, and Correlates with Immune Infiltration in Hepatocellular Carcinoma. J Hepatocell Carcinoma 2021;8:899-912. [PMID: 34395329 DOI: 10.2147/JHC.S320326] [Reference Citation Analysis]
141 Zhang H, Zhang W, Jiang L, Chen Y. Recent advances in systemic therapy for hepatocellular carcinoma. Biomark Res 2022;10:3. [PMID: 35000616 DOI: 10.1186/s40364-021-00350-4] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 8.0] [Reference Citation Analysis]
142 Sharma R, Motedayen Aval L. Beyond First-Line Immune Checkpoint Inhibitor Therapy in Patients With Hepatocellular Carcinoma. Front Immunol 2021;12:652007. [PMID: 33790915 DOI: 10.3389/fimmu.2021.652007] [Reference Citation Analysis]
143 Kudo M, Morimoto M, Moriguchi M, Izumi N, Takayama T, Yoshiji H, Hino K, Oikawa T, Chiba T, Motomura K, Kato J, Yasuchika K, Ido A, Sato T, Nakashima D, Ueshima K, Ikeda M, Okusaka T, Tamura K, Furuse J. A randomized, double-blind, placebo-controlled, phase 3 study of tivantinib in Japanese patients with MET-high hepatocellular carcinoma. Cancer Sci 2020;111:3759-69. [PMID: 32716114 DOI: 10.1111/cas.14582] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 4.5] [Reference Citation Analysis]
144 Rizzo A, Ricci AD. PD-L1, TMB, and other potential predictors of response to immunotherapy for hepatocellular carcinoma: how can they assist drug clinical trials? Expert Opin Investig Drugs 2021;:1-9. [PMID: 34429006 DOI: 10.1080/13543784.2021.1972969] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
145 Dahlgren D, Lennernäs H. Antibody-Drug Conjugates and Targeted Treatment Strategies for Hepatocellular Carcinoma: A Drug-Delivery Perspective. Molecules 2020;25:E2861. [PMID: 32575828 DOI: 10.3390/molecules25122861] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
146 Mroweh M, Roth G, Decaens T, Marche PN, Lerat H, Macek Jílková Z. Targeting Akt in Hepatocellular Carcinoma and Its Tumor Microenvironment. Int J Mol Sci 2021;22:1794. [PMID: 33670268 DOI: 10.3390/ijms22041794] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
147 Yang C, Guo Y, Qian R, Huang Y, Zhang L, Wang J, Huang X, Liu Z, Qin W, Wang C, Chen H, Ma X, Zhang D. Mapping the landscape of synthetic lethal interactions in liver cancer. Theranostics 2021;11:9038-53. [PMID: 34522226 DOI: 10.7150/thno.63416] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
148 Ragusa F, Panera N, Cardarelli S, Scarsella M, Bianchi M, Biagioni S, Giorgi M, Alisi A, Massimi M. Phosphodiesterase 4D Depletion/Inhibition Exerts Anti-Oncogenic Properties in Hepatocellular Carcinoma. Cancers (Basel) 2021;13:2182. [PMID: 34062786 DOI: 10.3390/cancers13092182] [Reference Citation Analysis]
149 Hsu C, Rimassa L, Sun HC, Vogel A, Kaseb AO. Immunotherapy in hepatocellular carcinoma: evaluation and management of adverse events associated with atezolizumab plus bevacizumab. Ther Adv Med Oncol 2021;13:17588359211031141. [PMID: 34377156 DOI: 10.1177/17588359211031141] [Reference Citation Analysis]
150 Ye S, Ni Y. lncRNA SNHG9 Promotes Cell Proliferation, Migration, and Invasion in Human Hepatocellular Carcinoma Cells by Increasing GSTP1 Methylation, as Revealed by CRISPR-dCas9. Front Mol Biosci 2021;8:649976. [PMID: 33898523 DOI: 10.3389/fmolb.2021.649976] [Reference Citation Analysis]
151 Zhao L, Chang N, Shi L, Li F, Meng F, Xie X, Xu Z, Wang F. Lenvatinib plus sintilimab versus lenvatinib monotherapy as first-line treatment for advanced HBV-related hepatocellular carcinoma: A retrospective, real-world study. Heliyon 2022;8:e09538. [PMID: 35706954 DOI: 10.1016/j.heliyon.2022.e09538] [Reference Citation Analysis]
152 Long H, Zhuang B, Huang G, Li X, Lin M, Long J, Xie X, Liu B. Safety and Local Efficacy of Laser Ablation for the Extrahepatic Metastasis of Hepatocellular Carcinoma: An Available Treatment Strategy. Coatings 2020;10:951. [DOI: 10.3390/coatings10100951] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
153 Yang Z, Wang S, Tian XY, Xie QF, Zhuang L, Li QY, Chen CZ, Zheng SS. Impact of treatment modalities on patients with recurrent hepatocellular carcinoma after liver transplantation: Preliminary experience. Hepatobiliary Pancreat Dis Int 2020;19:365-70. [PMID: 32553774 DOI: 10.1016/j.hbpd.2020.06.002] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 4.0] [Reference Citation Analysis]
154 Yang F, Yang J, Xiang W, Zhong BY, Li WC, Shen J, Zhang S, Yin Y, Sun HP, Wang WS, Zhu XL. Safety and Efficacy of Transarterial Chemoembolization Combined With Immune Checkpoint Inhibitors and Tyrosine Kinase Inhibitors for Hepatocellular Carcinoma. Front Oncol 2021;11:657512. [PMID: 35096555 DOI: 10.3389/fonc.2021.657512] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
155 Kalasekar SM, Garrido-Laguna I, Evason KJ. Immune Checkpoint Inhibitors in Combinations for Hepatocellular Carcinoma. Hepatology 2021;73:2591-3. [PMID: 33434363 DOI: 10.1002/hep.31706] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 6.0] [Reference Citation Analysis]
156 Li Y, Zheng Y, Wu L, Li J, Ji J, Yu Q, Dai W, Feng J, Wu J, Guo C. Current status of ctDNA in precision oncology for hepatocellular carcinoma. J Exp Clin Cancer Res 2021;40:140. [PMID: 33902698 DOI: 10.1186/s13046-021-01940-8] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]